

United Kingdom-Runcorn: Pharmaceutical products
OJ S 44/2017 03/03/2017
Contract award notice
Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1. Name and addresses

Official name: The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health)

Postal address: 2nd Floor, Rutland House

Town: Runcorn

NUTS code: UK United Kingdom

Postal code: WA7 2ES

Country: United Kingdom

E-mail: marie.thompson@dh.gsi.gov.uk

Telephone: +44 7448336519

Internet address(es):

Main address: <https://cmu.bravosolution.co.uk>

Address of the buyer profile: <https://cmu.bravosolution.co.uk>

I.4. Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5. Main activity

Other activity: public procurement

Section II: Object

II.1. Scope of the procurement

II.1.1. Title

NHS Pharmaceuticals Products Transition 2017_1.

Reference number: CM/PHG/15/5490

II.1.2. Main CPV code

33600000 Pharmaceutical products

II.1.3. Type of contract

Supplies

II.1.4. Short description

NHS Pharmaceuticals 2017_1

Offer reference number: CM/PHG/15/5490

Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months.

Potential periods of call-offs under the framework agreement:

North West and Eastern and North London: 1.5.2017 to 31.1.2018 (9 months),

South East and South London and North East and Yorkshire: 1.5.2017 to 31.10.2017 (6 months),

Central and South West: 1.5.2017 to 30.6.2018 (14 months).

II.1.6. Information about lots

This contract is divided into lots: yes

II.1.7. Total value of the procurement

Value excluding VAT: 4 200 000,00 GBP

II.2. Description

II.2.1. Title

LSNE: 1.5.2017 to 31.10.2017 (6 months)

Lot No: CM/PHG/15/5490/01

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: UK United Kingdom

II.2.4. Description of the procurement

NHS Pharmaceuticals Products Transition 2017_1 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months.

Potential periods of call-offs under the framework agreement:

CM/PHG/15/5490/01 — LSNE — 1.5.2017 to 31.10.2017 (6 months),

CM/PHG/15/5490/02 — NWLN — 1.5.2017 to 31.1.2018 (9 months),

CM/PHG/15/5490/03 — CESW — 1.5.2017 to 30.6.2018 (14 months).

II.2.5. Award criteria

Quality criterion - Name: Price / Weighting: In descending order

Quality criterion - Name: Quality — to include QA assessment of risk to patient / Weighting: In descending order

Quality criterion - Name: Market Risk / Weighting: In descending order

Cost criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: Not applicable

II.2.11. Information about options

Options: yes

Description of options:

Dates detailed below with options to extend up to a maximum of 28 months.

LSNE — 1.5.2017 to 31.10.2017 (6 months) NWLN — 1.5.2017 to 31.1.2018 (9 months)

CESW — 1.5.2017 to 30.6.2018 (14 months).

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

NWLN: 1.5.2017 to 31.1.2018 (9 months)

Lot No: CM/PHG/15/5490/02

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: UK United Kingdom

II.2.4. Description of the procurement

NHS Pharmaceuticals Products Transition 2017_1 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months.

Potential periods of call-offs under the framework agreement:

CM/PHG/15/5490/01 — LSNE — 1.5.2017 to 31.10.2017 (6 months),

CM/PHG/15/5490/02 — NWLN — 1.5.2017 to 31.1.2018 (9 months),

CM/PHG/15/5490/03 — CESW — 1.5.2017 to 30.6.2018 (14 months).

II.2.5. Award criteria

Quality criterion - Name: Price / Weighting: In descending order

Quality criterion - Name: Quality — to include QA assessment of risk to patient / Weighting: In descending order

Quality criterion - Name: Market Risk / Weighting: In descending order

Cost criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: Not applicable

II.2.11. Information about options

Options: yes

Description of options:

Dates detailed below with options to extend up to a maximum period of 28 months.

LSNE — 1.5.2017 to 31.10.2017 (6 months),

NWLN — 1.5.2017 to 31.1.2018 (9 months),

CESW — 1.5.2017 to 30.6.2018 (14 months).

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

CESW: 1.5.2017 to 30.6.2018 (14 months)

Lot No: CM/PHG/15/5490/03

II.2.2. Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: UK United Kingdom

II.2.4. Description of the procurement

NHS Pharmaceuticals Products Transition 2017_1 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months.

Potential periods of call-offs under the framework agreement:

CM/PHG/15/5490/01 — LSNE — 1.5.2017 to 31.10.2017 (6 months),

CM/PHG/15/5490/02 — NWLN — 1.5.2017 to 31.1.2018 (9 months),

CM/PHG/15/5490/03 — CESW — 1.5.2017 to 30.6.2018 (14 months).

II.2.5. Award criteria

Quality criterion - Name: Price / Weighting: In descending order

Quality criterion - Name: Quality — to include QA assessment of risk to patient / Weighting: In descending order

Quality criterion - Name: Market Risk / Weighting: In descending order

Cost criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: Not applicable

II.2.11. Information about options

Options: yes

Description of options:

Dates detailed below with options to extend up to a maximum period of 28 months.

LSNE — 1.5.2017 to 31.10.2017 (6 months),

NWLN — 1.5.2017 to 31.1.2018 (9 months),

CESW — 1.5.2017 to 30.6.2018 (14 months).

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

Section IV: Procedure

IV.1. Description

IV.1.1. Type of procedure

Open procedure

IV.1.3. Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

IV.1.8. Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

IV.2. Administrative information

IV.2.1. Previous publication concerning this procedure

Notice number in the OJ S: [2016/S 218-396382](#)

IV.2.8. Information about termination of dynamic purchasing system

IV.2.9. Information about termination of call for competition in the form of a prior information notice

Section V: Award of contract

Contract No: CM/PHG/15/5490

Lot No: 01

Title:

NHS Pharmaceuticals Products Transition 2017_1

A contract/lot is awarded: yes

V.2. Award of contract

V.2.1. Date of conclusion of the contract

13/02/2017

V.2.2. Information about tenders

Number of tenders received: 33

Number of tenders received from SMEs: 7

Number of tenders received by electronic means: 33

The contract has been awarded to a group of economic operators: no

V.2.3. Name and address of the contractor

Official name: Please see Section IV.3

Town: Please see Section IV.3

NUTS code: UK United Kingdom

Country: United Kingdom

The contractor is an SME: no

V.2.4. Information on value of the contract/lot

Total value of the contract/lot: 4 200 000,00 GBP

V.2.5. Information about subcontracting

Section VI: Complementary information

VI.3. Additional information

Please see list of awarded suppliers at the following website:

<https://www.gov.uk/contracts-finder>

VI.4. Procedures for review

VI.4.1. Review body

Official name: The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health)

Town: Runcorn

Country: United Kingdom

VI.5. Date of dispatch of this notice

02/03/2017